论文部分内容阅读
目的观察尿毒症患者行血液透析联合血液灌流治疗血清中PTH、β2-MG水平变化情况。方法取2015年3月至2016年3月84例稳定透析的尿毒症患者为研究对象,依据透析治疗方法不同将本组患者分为单纯行血液透析的对照组与同时行血液透析及血液灌流的联合组,将两组透析后血清中PTH、β2-MG水平作以比较。结果治疗前两组血清中PTH、β2-MG水平差异无统计学意义(P>0.05),治疗后联合组血清中PTH、β2-MG水平明显降低与对照组比较差异具备统计学意义(P<0.05)。结论常规血液透析联合血液灌流能进一步提高尿毒症患者体内PTH、β2-MG中分子毒素清除率,临床应用效果良好。
Objective To investigate the serum levels of PTH and β2-MG in patients with uremia treated by hemodialysis combined with hemoperfusion. Methods From March 2015 to March 2016, 84 patients with stable dialysis uremia were enrolled in this study. According to the different dialysis treatment methods, the patients were divided into simple hemodialysis group and hemodialysis group with hemodialysis The combination group, the two groups after dialysis serum PTH, β2-MG levels for comparison. Results There was no significant difference in the levels of PTH and β2-MG between the two groups before treatment (P> 0.05). After treatment, the levels of PTH and β2-MG in the combined group were significantly decreased compared with the control group (P < 0.05). Conclusion Conventional hemodialysis combined with hemoperfusion can further improve the clearance rate of molecular toxins in PTH and β2-MG in patients with uremia, and the clinical application is good.